Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.65 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771005 | 0.89 | AADAT (0.71) | AADATKYAT3CA1 | |
| SCHEMBL3768913 | 0.79 | AADAT (1.00) | AADATKYAT3 | |
| SCHEMBL3808023 | 0.79 | AADAT (1.00) | AADATKYAT3 | |
| SCHEMBL6763198 | 0.76 | AADAT (0.49) | AADATKYAT3SCN9ANPY1RDRD2 | |
| SCHEMBL6762978 | 0.75 | AADAT (0.59) | AADATKYAT3KMT2AL3MBTL1SCN9A | |
| SCHEMBL7837553 | 0.73 | XIAP (0.45) | NPY1R | |
| SCHEMBL6763220 | 0.73 | KYAT1 (0.40) | AADATKYAT3SCN9ANPY1RCA12 | |
| SCHEMBL6763129 | 0.73 | KMT2A (0.42) | KMT2AL3MBTL1SCN9ANPY1RDRD2 | |
| SCHEMBL10207849 | 0.73 | BACE1 (0.41) | AADATKYAT3 | |
| SCHEMBL7414589 | 0.73 | AADAT (0.53) | AADATKYAT3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | AADAT 2284/4885KYAT3 129/4885KMT2A 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.